Get the Stockscreener App
6.33
12.30%
0.6933
Pre-market:
6.29
-0.04
-0.63%
Redhill Biopharma Ltd Adr stock is traded at $6.33, with a volume of 30,494.
It is up +12.30% in the last 24 hours and down -2.62% over the past month.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
See More
Previous Close:
$5.6367
Open:
$6.24
24h Volume:
30,494
Relative Volume:
1.88
Market Cap:
$8.11M
Revenue:
$35.75M
Net Income/Loss:
$11.57M
P/E Ratio:
-1.6628
EPS:
-3.8069
Net Cash Flow:
$-26.25M
1W Performance:
+14.97%
1M Performance:
-2.62%
6M Performance:
-30.31%
1Y Performance:
-72.99%
1-Day Range:
$6.015
$6.43
1-Week Range:
$5.57
$6.43
52-Week Range:
$5.41
$31.50
Redhill Biopharma Ltd Adr Stock (RDHL) Company Profile
Compare RDHL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
6.33 | 8.11M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Redhill Biopharma Ltd Adr Stock (RDHL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-31-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-11-20 | Initiated | BTIG Research | Buy |
| Jul-12-19 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-12-19 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Jan-26-18 | Initiated | Nomura | Buy |
| Oct-06-17 | Initiated | Seaport Global Securities | Buy |
| Oct-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-17 | Reiterated | FBR & Co. | Outperform |
| Jul-27-16 | Reiterated | FBR Capital | Outperform |
| Sep-29-15 | Initiated | Nomura | Buy |
| Jul-29-15 | Reiterated | ROTH Capital | Buy |
| Jun-17-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-15 | Reiterated | ROTH Capital | Buy |
View All
Redhill Biopharma Ltd Adr Stock (RDHL) Latest News
RedHill stock rises on expanded Medicare coverage - Investing.com
GAMMA Investing LLC Buys 595 Shares of ArcelorMittal S.A. (NYSE:MT) - Defense World
RedHill wins $8 million judgment in New York court - Investing.com India
RedHill Biopharma: FDA Accepts TALICIA’s NDA - Investing.com
COVID-19 Competitive Landscape 2024 (Updated) - openPR
BARDA funds RedHill's opaganib for Ebola treatment - Investing.com
Medi-Cal extends Talicia access for 15 million Californians - Investing.com
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines - StockTitan
Can Redhill Biopharma Ltd. ADR Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
RDHL stock’s current quarter earnings estimates: What analysts predict? - US Post News
Talicia® Launched in the United Arab Emirates - StockTitan
Taking on analysts’ expectations and winning: Redhill Biopharma Ltd. ADR (RDHL) - SETE News
Redhill Biopharma stock hits 52-week high of $8.03 amid volatility - Investing.com
Opaganib shows promise in obesity, diabetes treatment - Investing.com India
Balance Sheet Breakdown: Redhill Biopharma Ltd. ADR (RDHL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Redhill Biopharma Ltd. ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
RedHill Biopharma Announces Positive Obesity and Diabetes Results with Opaganib - Investing.com
Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History - Yahoo Finance
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire
Its Stock Has Paid Off Big Time For Teck Resources Ltd - SETE News
Are Smart Investors Making the Right Decision? Redhill Biopharma Ltd. ADR (RDHL) - SETE News
Check Out Aveanna Healthcare Holdings Inc (AVAH)’s Trade Data Rather Than the Analysts’ Views - SETE News
RDHL’s Stock Tango: The Dance of Gains and Losses in 2023 - The InvestChronicle
Can you now get a good deal on Redhill Biopharma Ltd. ADR’s shares? - US Post News
Is ThredUp Inc (TDUP) positioned for future growth? - SETE News
A look into Redhill Biopharma Ltd. ADR (RDHL)’s deeper side - SETE News
Immuneering Corp (IMRX) expanding its growth trajectory ahead - SETE News
Cipher Mining Inc (CIFR) is looking forward to a strong quarter - SETE News
Nothing is Better Than Hut 8 Corp (HUT) stock at the moment - SETE News
Analytical Overview: Redhill Biopharma Ltd. ADR (RDHL)’s Ratios Tell a Financial Story - The Dwinnex
Redhill Biopharma Ltd. ADR [RDHL] Revenue clocked in at $35.52 million, down -68.49% YTD: What’s Next? - The DBT News
Redhill Biopharma Ltd. ADR Inc. (RDHL) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Should investors be concerned about RDHL’s high price-to-sales ratio? - US Post News
Exact Sciences Corp. (EXAS) Stock: A Year of Decreases and Increases - The InvestChronicle
New Outlook On Alibaba Group Holding Ltd ADR - Stocks Register
Baker Hughes Co (NASDAQ: BKR) Up 1.26%: This Is What Analysts Are Now Forecasting - Stocks Register
RedHill Biopharma finalizes agreement to enhance cash position - Investing.com
RedHill secures new US patent for H. pylori treatment Talicia - Investing.com
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042 - PR Newswire
Balancing Acidity: Exploring the Proton Pump Inhibitors Market - openPR
symbol__ Stock Quote Price and Forecast - CNN
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034 - PR Newswire
LLY Stock Quote Price and Forecast - CNN
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. - PR Newswire
Phil and RedHill Biopharma Partner to Increase Access to Talicia® - Business Wire
Peptic Ulcer Drugs Market Drivers Analysis | CAGR of 3.5% - Market.us
Benign Growth For RedHill Biopharma Ltd. (NASDAQ:RDHL) Underpins Stock's 41% Plummet - Yahoo Finance
RedHill’s Aemcolo® Granted FDA QIDP 5-Year Exclusivity Extension - BioSpace
RedHill presents New Talicia® and Movantik® data analyses at ACG 2022 - EurekAlert
Cathie Wood Predictions 2022 - New Trader U
RedHill presents new Talicia® data analyses at DDW 2022 - EurekAlert
Redhill Biopharma Ltd Adr Stock (RDHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):